Abstract
Background/aimHigh-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.Materials and methodsThe study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n = 39) and received mitoxantrone and melphalan followed by ASCT. The transplant regimen consisted of mitoxantrone (60 mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC).ResultsPrior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were in partial remission (PR), and 17% had stable or progressive disease. After high-dose chemotherapy and PBSC, 44 out of 51 patients achieved CR (86.2%). CR was achieved in 24 out of 33 patients (72.7%) who were transplanted in a marginally active phase of the disease. At a median followup of 25.4 months (1.8–131.3 months) after ASCT, 13 patients relapsed/progressed and 8 patients died. The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was 59.3%.ConclusionHigh-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractory lymphoma patients who are undergoing ASCT.
Highlights
Significant advances have been achieved in the treatment of non-Hodgkin’s lymphoma (NHL), 40%– 60% of patients still relapse or have treatment-resistant disease [1]
Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were in partial remission (PR), and 17% had stable or progressive disease
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is an effective conditioning regimen in relapsed/refractory lymphoma patients who are undergoing ASCT
Summary
Significant advances have been achieved in the treatment of non-Hodgkin’s lymphoma (NHL), 40%– 60% of patients still relapse or have treatment-resistant disease [1]. Many randomized studies have shown significant improvements in progression-free survival (PFS) and event-free survival (EFS) with ASCT in relapsed/refractory HL and NHL [1,2,3]. Other regimens, such as BCNU (carmustine), etoposide, cytarabine, melphalan (BEAM), are still more frequently preferred [4,5,6,7]. Other regimens used, such as bendamustine containing regimen [bendamustine, etoposide, cytarabine, melphalan (BeEAM)], fotemustine, etoposide, cytarabine, melphalan (FEAM), thiotepa containing regimen (TEAM), and using mitoxantrone instead of carmustine (NEAM) regimen
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
